nanoliposomal ceramide

Nanoliposomal ceramide is a **nanoparticle-based formulation of the bioactive lipid ceramide**, designed for improved delivery and enhanced therapeutic potential, primarily as an **anticancer agent**. Ceramide, a sphingolipid metabolite, deactivates multiple oncogenic signaling pathways, induces apoptosis, promotes cell death, and can induce necroptosis in cancer cells while largely sparing normal cells[3][9][1][5]. The nanoliposomal encapsulation addresses ceramide's poor solubility and short half-life, allowing efficient and targeted delivery in the body[2][4]. Keystone Nano developed this formulation for oncology indications. Preclinical and early clinical studies indicate a favorable safety profile, potential antitumor activity, and possible synergy with chemotherapy, targeted agents, and immunotherapy[3][2][4]. Nanoliposomal ceramide has shown activity in vitro, in animal models, and in human phase I studies for advanced solid tumors; a phase II trial is planned specifically for liver cancer[3][1][2]. It is also being explored in skincare products due to its barrier-restoring and anti-inflammatory properties[7].

Brand names

Clipos Nanoliposomal Ceramide

Other names

ceramide nanoliposomeceramide nanoliposomesCNL